UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER
THE
SECURITIES EXCHANGE ACT OF 1934
For
the month of March 2026
Commission
File Number: 001-41115
GENENTA
SCIENCE S.P.A.
(Translation
of registrant’s name into English)
Via
dell’Annunciata 31
20121
Milan, Italy
(Address
of Principal Executive Offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Other
Events
Proposed
Change to Corporate Name and Nasdaq Ticker Symbol
As previously disclosed in the Current
Report on Form 6-K of Genenta Science S.p.A. (the “Company”) filed with the U.S. Securities and Exchange Commission (the
“SEC”) on November 3, 2025, at the Company’s Ordinary and Extraordinary Shareholders’ Meeting held on October
29, 2025, the Company’s shareholders approved the proposed amendment to Article 4 of the Company’s by-laws to extend the
Company’s corporate purpose to include all sectors covered by the Italian Law Decree 21/2012 (i.e. Golden Power legislation). In
connection with the extension of the Company’s corporate purpose, the Company intended to adopt the new corporate name of “Saentra
Forge S.p.A.” and a new Nasdaq ticker symbol of “SAEN.” As previously disclosed in the Current Report on Form 6-K of
the Company filed with the SEC on January 27, 2026, the Company had scheduled an Extraordinary Shareholders’ Meeting (the “Meeting”)
to be held on March 25, 2026, at 5:00 p.m., on first call, and, if necessary, on March 26, 2026, at 5:00 p.m., on second call, for the
purpose of obtaining shareholder approval of the corporate name change. On March 23, 2026, the Company issued a notice of revocation,
announcing that the Board of Directors of the Company has resolved to revoke the call of the Meeting and the Meeting is hereby cancelled.
Following further analysis, it emerged that, at present, the name “Genenta” retains significant recognition, value and market
presence, having been associated with the Company’s history and identity for over a decade. Moreover, the approved extension of
the Company’s corporate purpose, to which the proposal for adopting a new corporate name was linked, is still in the initial phase
of development. The Notice is posted on the Company’s website at www.genenta.com under the Investors tab.
SUBMITTED
HEREWITH
Attached
to this Report for the month of March 2026, and incorporated by reference herein, is:
| Exhibit
No. |
|
Description
|
| 99.1 |
|
Notice of Revocation of the Extraordinary Shareholders’ Meeting of 25-26 March 2026. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
GENENTA SCIENCE S.P.A. |
| |
|
|
| |
By: |
/s/
Pierluigi Paracchi |
| |
Name:
|
Pierluigi
Paracchi |
| |
Title: |
Chief
Executive Officer |
Dated:
March 23, 2026
Exhibit
99.1
Genenta
Science S.p.A.
Registered
office: Milan, via Dell’Annunciata 31
Subscribed
and paid-up share capital of Euro 893,218.30
Tax
code and registration number with the Milan Monza-Brianza Lodi Companies’ Register: 08738490963
NOTICE
OF REVOCATION
OF
THE EXTRAORDINARY SHAREHOLDERS’ MEETING OF 25-26 MARCH 2026
It
is hereby announced that the Board of Directors of Genenta Science S.p.A. (the “Company”) has resolved to revoke the
call of the Extraordinary Shareholders’ Meeting previously scheduled for March 25, 2026, on first call, and March 26, 2026, on
second call, which had on its agenda the proposed amendment to Article 1 of the by-laws to change the Company’s name from Genenta
Science S.p.A. to Saentra Forge S.p.A.
Following
further analysis, it has emerged that, at present, the name “Genenta” retains significant recognition, value, and market
presence, having been associated with the Company’s history and identity for over a decade. Moreover, the approved extension
of the Company’s corporate purpose, to which the proposal for adopting a new corporate name was linked, is still in the initial
phase of development, and the proposed new name requires further development, positioning, and market recognition before replacing “Genenta,”
while the Company continues to regard the adoption of the new name as a strategic objective.
Milan,
23 March 2026
| |
For
the Board of Directors |
| |
|
| |
The
Chairman Pierluigi Paracchi |
